Blood-Typing is the progenitor of the entire field of personalized medicine. In the recently awarded 6-month Phase I, we proposed to take the first step in the development of an extremely-low-cost microarray test, "The Transfusion-Chip" (T-Chip) which convert the historical practice of Blood-Typing by serology into a simple inexpensive DNA test. Here, in this follow-on Phase II, we demonstrate substantial success in achieving key Phase I milestones: we have developed and optimized 22 PCR reactions, comprising the entire 7 gene blood group gene set [ABO, Rh, Duffy, Kidd, Kell, Dombrock &MNS];we have fabricated a Transfusion-Chip microarray prototype capable of analyzing all known genetic variation in the 7 gene set;and via technology that we had not yet invented when we filed the Phase I, we have developed a new variant of the original GenUSA microarray test which will drop the manufacturing cost of T-Chips to values as low as $1 per microarray. In Phase I we have also shown that the raw, unpurified OrageneTM-stabilized saliva can used as the basis for DNA based Blood-Typing on the T-Chip. We feel that the coupling of raw OrageneTM-stabilized saliva collection with the low cost T-Chip could become a unique technology pairing: because it would allow self-collection of DNA samples, at home, then low- cost ambient temperature shipping to centralized labs, to be followed by very-low-cost, very high throughput Blood-Typing on T-Chips. This model for population scale Blood-Typing will be the development focus in this Phase II: thereby enabling, we propose, an entirely new vision for population-scale blood banking &transfusion medicine, and in the process, will allow Blood- Typing to return, in the 21st century, to prominence as the model and gold standard for the field of genetically personalized medicine: as it first did a hundred years ago. Based on that model for population-scale blood group genetic testing, we propose the following set of Phase II Aims. SA1. Complete &Validate the Multiplex PCR Front-end to the Transfusion-Chip, for DNA Samples. SA2. Complete &Validate the Multiplex PCR Front-end to the Transfusion-Chip, for Raw Samples. SA3. Optimize &validate fabrication of the Transfusion-Chip in the 48 array per slide "$1 microarray" format. SA4. Modify existing GenUSA analysis software, RicimerTM, for automated blood group typing. SA5. Validate the Transfusion-Chip for purified DNA, raw blood &raw OrageneTM-stabilized saliva samples. Phase II Deliverables &Commercialization Plan. Upon completion of this Phase II, we will have ready a Transfusion-Chip kit prototype (microarrays, PCR reagents, Hybridization Reagents, Specialized Software) for subsequent Beta Testing. This kit will be prepared under manufacturing control (ISO 13845) similar to the HLA-Chip products from GenUSA which are currently being launched into tissue compatibility and immunogenetics markets. Subsequent to completion of Phase II, GenUSA will launch the T-Chip into the RUO Blood-Typing market and prepare simultaneously for FDA 510(k) submission to enter into the diagnostics market either alone, or in partnership with those with a proven market presence in transfusion medicine or at-home sample collection, or both.

Public Health Relevance

Blood group antigen typing by serology (Blood-Typing) has been, for a century, the progenitor and gold standard for the entire field of personalized medicine. Here we propose to pair two technologies recently developed at GenUSA [Raw Sample Genotyping + $1 Microarrays] to allow Blood-Typing to become a low-cost genetic test: A saliva or a dried blood sample could be self-collected at home in a simple clinic, then shipped by ordinary book-rate mail to a central lab, where upon arrival in the lab, Blood-Typing would be performed inexpensively via $1 microarray testing. We propose that this new vision for very-large-scale public health genetics will not only revolutionize the regulation of the blood supply and the practice of transfusion medicine, but will also serve as a model for a new approach to genetically personalized medicine: much as Blood-Typing, by serology, created (personalized) Transfusion Medicine a century ago.

National Institute of Health (NIH)
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Mitchell, Phyllis
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Genomics USA, Inc.
United States
Zip Code